Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced CKD Not Requiring Dialysis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Use of Oral Anticoagulants in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease Not Undergoing Dialysis

  • By

  • Qiaoxi Chen

  • Daniel E. Singer

  • Edouard L. Fu

  • Chun-Ting Yang

  • Kevin Pritchard

  • Rishi J. Desai

  • Kueiyu Joshua Lin

  • September 4, 2026

Share

  • 1

    Chronic kidney disease (CKD) affects 12% to 18% of individuals with atrial fibrillation (AF), increasing cardiovascular morbidity.

  • 2

    Oral anticoagulants (OACs) like warfarin and direct OACs (DOACs) reduce stroke risk in AF but increase bleeding risk.

  • 3

    Patients with advanced CKD (stage 4 or 5) were largely excluded from pivotal trials assessing OAC efficacy and safety.

  • 4

    Apixaban is the only DOAC approved for preventing stroke in AF patients with severe kidney impairment.

  • 5

    The study compared apixaban, warfarin, and no OAC use among AF patients with advanced CKD not undergoing dialysis.

Original Source(s)

Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced CKD Not Requiring Dialysis

  • by Qiaoxi Chen, Daniel E. Singer, Edouard L. Fu, Chun-Ting Yang, Kevin Pritchard, Rishi J. Desai, Kueiyu Joshua Lin

  • September 4, 2026

Related Content

Exploring nurse- and allied health professional-led opportunistic atrial fibrillation screening with artificial intelligence-enabled devices in community and primary care

Clinical characteristics and risk factors of atrial fibrillation detection after acute ischemic stroke

Synergistic effects of early sequential enhanced external counterpulsation and electric tilt table training on functional recovery in ischemic stroke: study protocol of a randomized controlled trial